Navigation ▼

Zur Kurzanzeige

dc.contributor.advisor Wilken, Bernd Prof. Dr.
dc.contributor.author Eichler, Regina
dc.date.accessioned 2016-03-16T10:47:40Z
dc.date.available 2016-04-10T22:50:05Z
dc.date.issued 2016-03-16
dc.identifier.uri http://hdl.handle.net/11858/00-1735-0000-0028-8701-1
dc.language.iso deu de
dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject.ddc 610 de
dc.title Botulinumtoxintherapie bei kindlicher Zerebralparese - Wirksamkeit und Elternbewertung de
dc.type doctoralThesis de
dc.title.translated Botulinum toxin therapy in children with cerebral palsy - efficieny and assessment of parents de
dc.contributor.referee Laskawi, Rainer Prof. Dr.
dc.date.examination 2016-04-06
dc.description.abstracteng Objectives: Botulinumtoxin A (BtxA) is very successful in locally treatment of movement disorders such as spasticity and dystonia. Multileveltherapy is a further development of the usual treatment with Botulinumtoxin which means injections into several groups of muscles. The objective is to show the influence of multileveltherapy and the age at the beginning of the treatment. Methods: Multileveltherapy means a treatment with BtxA injections of at least two groups of muscles leading to different movements using two joints. This is a retrospective study of 196 children who received BtxA injections for the treatment of cerebral movement disorders. The children either received a local therapy or a multileveltherapy. Dosage of BtxA was according to the number of treated muscles; all injections were performed with ultrasound guidance. To value the success of therapy individual aims of treatment were defined. Evaluation of parents and physiotherapists were most important. They were collected with a standardized questionnaire.  Results: 196 children received BtxA injections. In 84 children a local treatment was performed, 112 children received a multileveltherapy. From all children who received multileveltherapy 77,4% reached the defined aims of treatment. Regarding all treated patients 68,9% of the children reached the defined aim. Evaluations of parents and physiotherapists, which reflected quality of life and reaching the defined aims, showed a successful therapy in 80,9% of patients with multilevetherapy. Regarding all patients parents and physiotherapists saw a successful treatment in 75,7%. Neither in regarding all treated patients nor in the patients with multileveltherapy there was a significant difference in the success of treatment related to the age of the children at the beginning of therapy. Conclusions: Treatment with BtxA in cerebral movement disorders such as spasticity is successful. Treatment with multileveltherapy shows a better outcome in reaching defined aims of treatment. To reach better long term effects in the treatment with BtxA it is necessary to consider the whole statics of children. Most surprising conclusion was that success of treatment was not influenced by the age of the children at the beginning of treatment. This shows that an attempt of treatment with BtxA might be useful even in older patients. de
dc.contributor.coReferee Schön, Margarete Prof. Dr.
dc.subject.eng botulinum toxin de
dc.subject.eng cerebral palsy de
dc.subject.eng multileveltherapy de
dc.subject.eng cerebral movement disorders de
dc.identifier.urn urn:nbn:de:gbv:7-11858/00-1735-0000-0028-8701-1-8
dc.affiliation.institute Medizinische Fakultät de
dc.subject.gokfull Medizin (PPN619874732) de
dc.subject.gokfull Pädiatrie / Neonatologie / Kinderchirurgie - Allgemein- und Gesamtdarstellungen (PPN619876093) de
dc.description.embargoed 2016-04-10
dc.identifier.ppn 852450524

Dateien

Das Dokument erscheint in:

Zur Kurzanzeige